Church & Dwight Hopes Oral Care, Orajel Reverse Personal Care Slump
This article was originally published in The Tan Sheet
Executive Summary
The firm seeks to make personal care a growth engine again, hoping single-dose Orajel can overcome competition and FDA concerns about benzocaine overdosing.
You may also be interested in...
C&D’s Naturals Could Help Retain Orajel Customers After Benzocaine Warning
Church & Dwight’s Baby Orajel Naturals could fill a potential void in the teething relief market created by FDA’s recent warning children under 2 years should not use the painkiller benzocaine.
FDA Warns Of Deadly Benzocaine Risks, Label Changes Might Be On The Way
Concern that products with the painkiller benzocaine are linked to rare but serious and potentially fatal adverse events prompted an FDA consumer warning and could lead to label and package changes.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.